Forbes Ranks BioReliance #1 in Earnings Per Share Growth on Annual List of 200 Entrepreneurial Growth Companies
27 Octubre 2003 - 3:30PM
PR Newswire (US)
Forbes Ranks BioReliance #1 in Earnings Per Share Growth on Annual
List of 200 Entrepreneurial Growth Companies ROCKVILLE, Md., Oct.
27 /PRNewswire-FirstCall/ -- BioReliance Corporation announced
today that it has been named to Forbes magazine's annual list of
"Hot Shots: 200 Up and Coming Companies" for 2003. BioReliance was
ranked "Number 1" in Earnings per Share Growth over the past five
years and number 139 overall among this select group of smaller
public companies. In developing its annual ranking, Forbes
collaborated with William O'Neil & Company in the compilation
of the list of 200, which consists of fast growing, profitable
public companies with revenues between $5 million and $600 million.
For the final ranking, equal weight was given to growth in sales,
earnings and return on equity for the past five years and the
latest 12 months. Appearing for the first time on the annual
listing, BioReliance was ranked number 139 overall and "Number 1"
in earnings per share growth among the 200 companies comprising the
list. Capers McDonald, President and Chief Executive Officer of
BioReliance, said, "We are honored in this recognition by Forbes.
We believe that it reflects, in part, the high level of dedication
by everyone at BioReliance to the productivity and growth of our
company. This result, accomplished over the past five years, is
driven by our ongoing efforts in quality, science and service. We
are committed to providing our customers with the very highest
levels of support, wherever we do business, and to increasing
shareholder value in that process." About BioReliance BioReliance
Corporation is a leading, global contract service organization
providing integrated testing, development and manufacturing
services for biologics and other biomedical products to
biotechnology and pharmaceutical companies worldwide. The Company
believes it is the largest provider of outsourcing services focused
on the expanding biologics sector of the pharmaceutical industry.
This press release contains forward-looking statements that
describe certain BioReliance communications. As and when made,
management believes that these forward-looking statements are
reasonable. BioReliance undertakes no obligation to revise or
publicly release the results of any revision to these
forward-looking statements. Therefore, readers are cautioned not to
place undue reliance on these forward-looking statements since new
risk factors emerge from time to time, and it is not possible for
management to predict all such risk factors, nor can it assess the
impact of all such risk factors on BioReliance's business or the
extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any
forward-looking statements. DATASOURCE: BioReliance Corporation
CONTACT: John L. Coker, Sr. Vice President, Finance and
Administration and Chief Financial Officer of BioReliance
Corporation, +1-301-762-5260; or General Info, Marilynn Meek,
+1-212-445-8451, or Analysts, Julie Tu, +1-212-445-8456, both of
FRB Weber Shandwick
Copyright
Bioreliance (NASDAQ:BREL)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Bioreliance (NASDAQ:BREL)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024
Real-Time news about Bioreliance Corp (MM) (NASDAQ): 0 recent articles
Más de Bioreliance (MM) Artículos de Noticias